Te­va talks tough on cuts; Take­da bol­sters start­up with a ded­i­cat­ed car­dio dis­cov­ery team

→ With its share price plum­met­ing as the rev­enue num­bers de­te­ri­o­rate at a rapid pace, Is­rael’s trou­bled Te­va talked up deep cuts to­day, with plans for ax­ing thou­sands of jobs as well as a com­plete re­vamp on man­u­fac­tur­ing that in­cludes shut­ter­ing or di­vest­ing nine fa­cil­i­ties.

→ Cam­bridge, MA-based start­up Car­du­ri­on is get­ting start­ed with a cre­ative al­liance with Take­da. The phar­ma com­pa­ny — which has been re­vamp­ing R&D — is pro­vid­ing the lit­tle biotech with a 12-per­son car­dio re­search team in Japan for its dis­cov­ery work, look­ing to kin­dle some R&D mag­ic in the al­liance of a glob­al play­er and a biotech up­start. Car­du­ri­on is run by two in­dus­try vet­er­ans: CEO Daniel Bloom­field and Michael Mendel­sohn, founder and ex­ec­u­tive chair­man. The cre­ation of this part­ner­ship with Car­du­ri­on fol­lows Take­da’s strat­e­gy to lever­age ex­ter­nal in­no­va­tion by plac­ing se­lect­ed as­sets and out­stand­ing sci­en­tists in­to en­tre­pre­neur­ial en­vi­ron­ments,” said An­drew Plump, chief med­ical and sci­en­tif­ic of­fi­cer, Take­da. “By lever­ag­ing the high lev­el of ther­a­peu­tic ex­per­tise at Take­da’s Shonan Re­search Cen­ter to sup­port drug dis­cov­ery, we’re mo­ti­vat­ing sci­en­tists to come to­geth­er to de­liv­er on our promise of serv­ing pa­tients with ex­ist­ing un­met needs.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.